Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00672451 · ClinicalTrials.gov registry record · Phase 2
Rhubarb and Angiotensin Converting Enzyme Inhibitor
A Phase 2 study, sponsored by Wake Forest University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00672451: Clinical Trial Phase 2 study, sponsored by Wake Forest University.
NCT00672451 is a Phase 2 study that was terminated before completion, run by Wake Forest University. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00672451, a Phase 2 study, was terminated before completion, sponsored by Wake Forest University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Rhubarb extract is a chinese herbal preparation that is used in china and other asian countries to treat constipation and chronic kidney disease. Use of angiotensin converting enzyme inhibitors (ACEI) in diabetic kidney disease has been shown to be beneficial in slowing progression. The purpose of this study is to determine the combined effect of rhubarb plus enalapril (an ACEI)in slowing the rate of decline of CKD in people with kidney disease from diabetes.
Interventions
- DIETARY_SUPPLEMENT placebo
- DIETARY_SUPPLEMENT rhubarb extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Why NCT00672451 stopped before completion
NCT00672451 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00672451 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00672451 about?
NCT00672451 is a clinical study titled "Rhubarb and Angiotensin Converting Enzyme Inhibitor". Rhubarb extract is a chinese herbal preparation that is used in china and other asian countries to treat constipation and chronic kidney disease. Use of angiotensin converting enzyme inhibitors (ACEI) in diabetic kidney disease has been shown to be beneficial in slowing progression. The purpose of t...
What is the current status of trial NCT00672451?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2008-01. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00672451?
The interventions under investigation include: placebo (DIETARY_SUPPLEMENT), rhubarb extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00672451?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00672451's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia